Neuralab Limited

Elan Pharmaceuticals, Inc.

Janssen Alzheimer Immunotherapy

Athena Neurosciences, Inc.

Eli Lilly and Company

University of California

Neotope Biosciences Limited

Other

Wyeth

The Brigham and Women's Hospital, Inc.

Janssen Sciences Ireland Uc

Elan Pharma International Limited

Leland Stanford Junior University

The University of Tennessee Research Foundation

Prothena Biosciences Limited

Dale Bernard Schenk

Peter A Seubert

Peter Andrew Seubert

Kate Dora Games

Carmen Vigo-Pelfrey

Robin McDaid Barbour

Tamie Chilcote

Edward Rockenstein

Manuel J Buttini

Theodore A Yednock

Eliezer Masliah

Dennis J Selkoe

Lawrence C Fritz

Jonathan Wall

Jose William Saldanha

Eliezar Masliah

Tamie J Chilcote

Guriq Basi

José W Saldanha

Russell E Rydel

Lisa Clair McConlogue

Martin Citron

Nicki Vasquez

Michael G Schlossmacher

Tarlochan S Nijjar

Sukanto Sinha

Lisa Claire McConlogue

Guriqbal Basi

Jun Zhao

Philip W Payne

Kelly L Johnson

Kelly Johnson-Wood

William I Weis

Hadar Hana Feinberg

Nicki J Vasquez

Dora Kate Games

Ted Yednock

The present invention provides crystals including amino acids 1-7 of SEQ ID NO:1 and a Fab fragment of 12A11, 12B4, 10D5 or 3D6, as well as of amino acids 1-40 of SEQ ID NO:1 and a Fab fragment of 12A11 or 3D6, as well as methods for preparing the crystals. The present invention also provides a computer implemented method for analyzing binding of a candidate antibody fragment to a peptide including an epitope of amino acids 1-7 of SEQ ID NO:1, a method for identifying an antibody fragment that can mimic the Fab fragment of 12A11, a method for identifying an antibody fragment that can mimic the Fab fragment of 3D6, a method for identifying a candidate antibody fragment that binds to a peptide including an epitope of amino acids 1-7 of SEQ ID NO:1, and a method for designing a humanized antibody that binds to a peptide comprising an epitope of amino acids 1-7 of SEQ ID NO:1.

Hybrid amyloid-beta antibodies

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&#x3b2; in the brain of a patient. Preferred agents include humanized antibodies.

Humanized antibodies that recognize beta amyloid peptide

The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Treatment and delay of outset of synucleinopathic and amyloidogenic disease

Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.

Treatment and prophylaxis of amyloidosis

The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.

APOE immunotherapy

Prevention and treatment of synucleinopathic and amyloidogenic disease

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&#x3b2; in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A&#x3b2; and antibodies binding to the same.

Prevention and treatment of amyloidogenic disease

Detection of amyloid deposits using anti-amyloid antibodies

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A&#x3b2; peptide, active fragments thereof or an antibody thereto.

Chimeric, humanized, or human antibody 2A4

Anti-amyloid antibodies

Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.

Prevention and treatment of amyloidogenic diseases

Growing community of inventors

Burlingame, CA, United States of America

Dale Bernard Schenk